Efficacy and safety of pramipexole in restless legs syndrome

Neurology

Volumn 67, Issue 6, 2006, Pages 1034-1039

  Winkelman, J W ^a   Sethi, K D ^b   Kushida, C A ^c   Becker, P M ^d   Koester, J ^e   Cappola, J J ^f   Reess, J ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRAMIPEXOLE;

ADULT; AGED; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESTLESS LEGS SYNDROME; RHINOPHARYNGITIS; SLEEP; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIOXIDANTS; BENZOTHIAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; RESTLESS LEGS SYNDROME; SEVERITY OF ILLNESS INDEX; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 33748996775     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000231513.23919.a1     Document Type: Article

References (18)

1. Silber MH, Ehrenberg BL, Allen RP, et al., for the Medical Advisory Board of the Restless Legs Syndrome Foundation. An algorithm for the management of restless legs syndrome. Mayo Clin Proc 2004;79:916-922.
2. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 2002;41:261-309.
3. Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 1999;52:938-943.
4. Montplaisir J, Denesle R, Petit D. Pramipexole in the treatment of restless legs syndrome: a follow-up study. Eur J Neurol 2000;7(suppl 1):27-31.
5. Walters AS. Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Mov Disord 1995;10:634-642.
6. Hening WA, Allen RP. Restless legs syndrome (RLS): the continuing development of diagnostic standards and severity measures. Sleep Med 2003;4:95-97.
7. Walters AS, LeBrocq C, Dhar A, et al., for the International Restless Legs Syndrome Study Group. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003;4:121-132.
8. National Institute of Mental Health (NIMH). Early clinical drug evaluation unit (ECDEU). Clinical Global Impressions. In: Guy W, ed. ECDEU assessment manual for psychopharmacology, rev ed. Rockville, MD: NIMH; 1976.
9. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-545.
10. Abetz L, Vallow SM, Kirsch J, Allen RP, Washburn T, Earley CJ. Validation of the restless Legs Syndrome Quality of Life questionnaire. Value Health 2005;8:157-167.
11. Telstad W, Sorensen O, Larsen S, Lillevold PE, Stensrud P, Nyberg-Hansen R. Treatment of the restless legs syndrome with carbamazepine: a double blind study. Br Med J (Clin Res Ed) 1984;288:444-446.
12. Boghen D, Lamothe L, Elie R, Godbout R, Montplaisir J. The treatment of the restless legs syndrome with clonazepam: a prospective controlled study. Can J Neurol Sci 1986;13:245-247.
13. Trenkwalder C, Stiasny K, Pollmacher T, et al. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep 1995;18:681-688.
14. Stiasny-Kolster K, Kohnen R, Schollmayer E, Moller JC, Oertel WH for the Rotigotine Sp 666 Study Group. Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord 2004;19:1432-1438.
15. Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. for the Therapy with Ropinirole: Efficacy and Tolerability in RLS 1 Study Group. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004;75:92-97.
16. Walters AS, Ondo WG, Dreykluft T, Grunstein R, Lee D, Sethi K for the TREAT RLS 2 Study Group. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 2004;19:1414-1423.
17. Kushida CA, Allen RP, Atkinson MJ. Modeling the causal relationships between symptoms associated with restless legs syndrome and the patient-reported impact of RLS. Sleep Med 2004;5:485-488.
18. Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005;165:1286-1292.